“This is not the last word on this endovascular treatment for MS,” Siddiqui concluded. “This is the first word because this was the first double-blinded, randomized sham-controlled trial on the subject. However, these findings lead us to caution strongly against the general acceptance of this invasive procedure for MS patients.”


MS patients did not benefit from CCSVI intervention, landmark pilot study of 'liberation treatment'.
www.buffalo.edu
Procedure is safe but does not improve MS outcomes, a finding that the UB investigators call “surprising and unexpected”